Close Menu

NEW YORK (GenomeWeb) – GenomeDx announced today that its prostate cancer classifier tests have been approved by the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP).

The approval covers GenomeDx's Decipher Biopsy and Decipher Post-Op tests, which use genomic data to improve clinical decision-making following biopsy or radical prostatectomy, respectively, in men with prostate cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.